Axios on MSN15m
Copycat Ozempic makers brace for crackdown
Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...
Hosted on MSN2h
Hims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide Update
Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...
The 'next important test for AI bulls' happens this week with Nvidia's earnings
BofA analysts, in a note this month, said Nvidia's results will mark the "next important test for AI bulls," adding that the company's per-share profit "could have enough substance even if less sizzle ...
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...